Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America

Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022

Moderna also supplies the Company's COVID-19 vaccine to 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries through GAVI, the Vaccine Alliance agreement

CAMBRIDGE, MA / ACCESSWIRE / February 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced a distribution service agreement with Adium Pharma S.A., a leading private Latin American pharmaceutical company, to support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina.

"Our new partnership with Adium will help ensure broad access and delivery of our Moderna COVID-19 vaccine to people across Latin America," said Stéphane Bancel, Chief Executive Officer of Moderna. "A presence in Latin America is a key part of our global commercial strategy. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against COVID-19 and future vaccine-preventable diseases."

Moderna has a commercial presence in 11 countries worldwide (Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, UK, U.S.) and recently announced plans to increase its commercial footprint across ten additional markets in Asia-Pacific (Hong Kong, Malaysia, Singapore, Taiwan) and Europe (Belgium, Denmark, the Netherlands, Norway, Poland, Sweden) in 2022.

The Company also has commercial agreements with distributors to supply the Company's COVID-19 vaccine in 45 countries, with Zuellig Pharma in the Asia Pacific, Medison Pharma in Central Eastern Europe and Israel, and Adium Pharma in Latin America. In addition, Moderna announced an agreement with Gavi, the Vaccine Alliance, to supply up to 650 million doses of the Company's COVID-19 Vaccine across 2021 and 2022, covering the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries.

Regulators have approved Moderna's COVID-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807 million doses of Moderna's COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income markets. In Latin America, Moderna has established bilateral and supranational supply agreements in 15 countries.

About Moderna

In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's distribution service agreement with Adium Pharma S.A. to support the commercialization of the Moderna's COVID-19 Vaccine, Spikevax across Latin America and the scope of countries covered under that agreement, and plans to expand the Company's commercial presence to ten additional markets in 2022. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent lings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

Moderna Contacts

Media:
Luke Mircea Willats
Director, Corporate Communications
luke.mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.